
We have changed our name to hVIVO plc, ticker: HVO. Follow @hVIVO_UK to keep up to date.
London, United Kingdom
Joined December 2017
- Tweets676
- Following568
- Followers1.7K
- Likes378
Today we officially change our name to hVIVO on @LSEGplc AIM and @euronext_ie📣
Find all the latest news & investor information here:
hvivo.com
👉Don’t forget to start following @hVIVO_UK.
📈 Our new ticker is #HVO
Further to our recent announcement, #ORPH's name change to hVIVO plc has now been completed and is expected to take effect on @LSEGplc AIM & @euronext_ie from 8.00 am tomorrow.
Learn more:
londonstockexchange.com/news…
Follow us on @hVIVO_UK to keep up to date!
#HVO
Last week we announced our upcoming Capital Markets Day on Wednesday 2 November 2022 at 9.30 am - 12.00 pm (GMT).
Register below if you would like to attend virtually ⏬
stream.brrmedia.co.uk/broadc…
#HVO #CapitalMarketsDay #ORPH
We're holding a Capital Markets Day on 2 Nov 2022.
🧑Chaired by our #CEO
🔬 Insights into the business
📈 Human challenge trials & the growing market
🗣️ Guest speakers, including @p_openshaw
❓ Q&A with #ORPH management
londonstockexchange.com/news…
#HVO
Stephen Pinkerton has been appointed as #CFO and Exec Director of #ORPH.
Wealth of experience:
☑️ 25 years in Senior Financial Roles
☑️ Served as Commercial Financial Director @hVIVO_UK since 2017 driving initiatives to improve profitability
londonstockexchange.com/news…
#HVO
Our new investors section will be going live alongside our name change launch, which is expected to take place on 26 October 2022.
Stay tuned...👀 and don't forget to follow @hVIVO_UK for updates
#WatchThisSpace #StayTuned #Rebrand #HVO #hVIVO #ORPH
Positive #data from a peer-reviewed study evaluating the in vitro efficacy of FLU-v, @ImutexLtd broad spectrum #influenza #vaccine candidate, has been published in the scientific journal @Vaccines.
Learn more:
londonstockexchange.com/news…
#HVO #Imutex #Flu #ORPH
This morning our #CEO purchased 510,204 #ORPH shares at 9.8 pence per share.
"…The purchase of shares in the Company demonstrates both my commitment and my confidence in our long-term growth strategy…”
Yamin 'Mo' Khan
londonstockexchange.com/news…
Some of our @hVIVO_UK team will be attending and presenting at the #OptionsXI for the Control of #Influenza conference & the 12th International #RSV Symposium in Belfast this week
Learn more: londonstockexchange.com/news…
#infectiousdisease #research #clinicaltrials
Here @proactive_UK's @TheChrisRhodes & analyst Daniel Appiah discuss #ORPH's H1 results.
They highlight increasing demand for challenge trials & growing contract order book, which stands at over £80mln — almost 3X the value during the same period FY2021
youtube.com/watch?v=t8vLL10m…
Our interims presentation deck used during the @investormeetco presentation on Thursday 8 September is now available to download ⬇️.
Click below👇 to view & download PDF:
openorphan.com/investors/rep…
#HVO #ORPH #Interim #Results
If you missed last weeks @investormeetco presentation featuring our #CEO & #CFO, you can watch it here:
youtube.com/watch?v=GRsTsN4E…
Highlights:
☑️ Operational & Financial Overview H1 2022
☑️ Name change to @hVIVO_UK & ticker: HVO
☑️ H2 plans & outlook
#HVO













